Neurocrine Biosciences, Inc. (BIT:1NBIX)
 120.05
 0.00 (0.00%)
  Last updated: Oct 31, 2025, 9:00 AM CET
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $794.90M USD in the quarter ending September 30, 2025, with 27.78% growth. This brings the company's revenue in the last twelve months to $2.68B, up 19.61% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm) 
 $2.68B
Revenue Growth 
 +19.61%
P/S Ratio 
 5.41
Revenue / Employee 
 $1.49M
Employees 
 1,800
Market Cap 
12.38B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% | 
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% | 
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% | 
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% | 
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Stellantis | 146.12B | 
| Eni S.p.A. | 86.56B | 
| Enel SpA | 77.79B | 
| Assicurazioni Generali | 56.79B | 
| Intesa Sanpaolo | 25.38B | 
| UniCredit | 24.85B | 
| Prysmian | 19.49B | 
| Leonardo S.p.a. | 18.70B |